CORT
Corcept TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
The bull case is that March 2026 approval converted ROSELLA from a trial story into a launch story, and the April 2026 full data package strengthened confidence that Lifyorli can become a meaningful ovarian-cancer franchise. Corcept also retains a profitable base business, 2026 revenue guidance of $900-$1,000 million, and $532.4 million of cash, cash equivalents and marketable securities at year-end 2025 [#10-K-2026-02-24] [#IR-2026-02-24].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.8.
What can break
Corcept's 2025 net product revenue still came from its existing product base, so oncology-commercial traction must be demonstrated rather than assumed [#10-K-2026-02-24].
Momentum
98
Value
58
Sentiment
1
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $50.00 · Bull $60.00 · Bear $34.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $106.00
Why
Momentum98 · Δ7d +1.8
Value58 · Δ7d -0.0
Sentiment1 · Δ7d -1.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
98
26% active weight
Current posture
7d trendFlat
Δ7d
+1.8
Δ21d
+1.0
Value
58
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
1
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.7
Δ21d
-6.1
Why this grade
Composite grade C. Momentum 97.9 / Value 58.3 / Sentiment 0.9
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$9.76B
Beta
0.24
Shares Out
107.35M
P/E (TTM)
39.5
P/S (TTM)
4.96
P/FCF (TTM)
22.54
Rev YoY
+4.9%
EPS YoY
-276.5%
Gross Margin
+98.3%
Op Margin
+8.8%
Net Debt
-$366.05M
Current Ratio
2.83
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology